|
|
|
|
FIELD OF EXPERTISE
- Breast Cancer
- Hereditary Breast–Ovarian Cancer Syndromes (HBOC)
- BRCA1/2
- (Non-Coding) RNA
- Loss of Heterozygosity (LOH) / Second hit
- Bioinformatics
- Long-read sequencing
PROJECTS
Background
Currently I am mainly active as a bioinformatician at the Center for Medical Genetics Ghent, where the bulk of my work revolves around ophthalmogenetics. Here I’m involved in data analysis, experimental design with an eye on data handling and interpretation and workflow implementation for whole exome/genome/transcriptome sequencing, long-read sequencing, among other techniques. In that capacity I provide data analysis and experimental design support for Lab Claes, where I studied the role of small non-coding RNAs in somatic inactivation of BRCA1 and BRCA2 during my PhD.
Aim
Prof. Claes’ lab is currently involved in long-read sequencing and (transcriptome-wide) alternative splicing. My role consists in this project is building pipelines for data analysis and aiding with data interpretation. More precise we are deciphering the full range of ATM isoforms in human using Oxford Nanopore sequencing in collaboration with the ENIGMA consortium. ENIGMA focusses on the interpretation of genetic variants in breast cancer genes.
Currently I am mainly active as a bioinformatician at the Center for Medical Genetics Ghent, where the bulk of my work revolves around ophthalmogenetics. Here I’m involved in data analysis, experimental design with an eye on data handling and interpretation and workflow implementation for whole exome/genome/transcriptome sequencing, long-read sequencing, among other techniques. In that capacity I provide data analysis and experimental design support for Lab Claes, where I studied the role of small non-coding RNAs in somatic inactivation of BRCA1 and BRCA2 during my PhD.
Aim
Prof. Claes’ lab is currently involved in long-read sequencing and (transcriptome-wide) alternative splicing. My role consists in this project is building pipelines for data analysis and aiding with data interpretation. More precise we are deciphering the full range of ATM isoforms in human using Oxford Nanopore sequencing in collaboration with the ENIGMA consortium. ENIGMA focusses on the interpretation of genetic variants in breast cancer genes.
GRANTS AND AWARDS
- FWO Travel grant for a course abroad, ecSeq Bioinformatics RNA-Seq course (Germany, 2019)
- Travel Grant, Faculty of Medicine and Health Sciences (Ghent University, 2016)
- Doctoral (PhD) Grant Strategic Basic Research (IWT 131739, jan 2014 - dec 2017)
DEGREES
- Doctor of Health Sciences, Defended June 2019 (dissertation: 'Second hits in BRCA1- and BRCA2-associated breast and ovarian cancer - connecting coding to non-coding mechanisms of inactivation')
- Master of Bioscience Engineering - Cell and Gene Biotechnology (Ghent University, 2013)
- Bachelor of Bioscience Engineering (University of Antwerp, 2011)